223 related articles for article (PubMed ID: 23756180)
1. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.
Kim KH; Dmitriev IP; Saddekni S; Kashentseva EA; Harris RD; Aurigemma R; Bae S; Singh KP; Siegal GP; Curiel DT; Alvarez RD
Gynecol Oncol; 2013 Sep; 130(3):518-24. PubMed ID: 23756180
[TBL] [Abstract][Full Text] [Related]
2. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
Kim KH; Ryan MJ; Estep JE; Miniard BM; Rudge TL; Peggins JO; Broadt TL; Wang M; Preuss MA; Siegal GP; Hemminki A; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
Hum Gene Ther; 2011 Jul; 22(7):821-8. PubMed ID: 21171861
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.
Kimball KJ; Preuss MA; Barnes MN; Wang M; Siegal GP; Wan W; Kuo H; Saddekni S; Stockard CR; Grizzle WE; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
Clin Cancer Res; 2010 Nov; 16(21):5277-87. PubMed ID: 20978148
[TBL] [Abstract][Full Text] [Related]
4. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
Page JG; Tian B; Schweikart K; Tomaszewski J; Harris R; Broadt T; Polley-Nelson J; Noker PE; Wang M; Makhija S; Aurigemma R; Curiel DT; Alvarez RD
Am J Obstet Gynecol; 2007 Apr; 196(4):389.e1-9; discussion 389.e9-10. PubMed ID: 17403430
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer.
Kim KH; Dmitriev I; O'Malley JP; Wang M; Saddekni S; You Z; Preuss MA; Harris RD; Aurigemma R; Siegal GP; Zinn KR; Curiel DT; Alvarez RD
Clin Cancer Res; 2012 Jun; 18(12):3440-51. PubMed ID: 22510347
[TBL] [Abstract][Full Text] [Related]
6. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
8. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
10. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
[TBL] [Abstract][Full Text] [Related]
11. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
[TBL] [Abstract][Full Text] [Related]
12. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.
Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Curiel DT
J Ovarian Res; 2016 Jun; 9(1):38. PubMed ID: 27349517
[TBL] [Abstract][Full Text] [Related]
14. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
15. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
16. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Raki M; Kanerva A; Ristimaki A; Desmond RA; Chen DT; Ranki T; Sarkioja M; Kangasniemi L; Hemminki A
Gene Ther; 2005 Aug; 12(15):1198-205. PubMed ID: 15800658
[TBL] [Abstract][Full Text] [Related]
17. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
[TBL] [Abstract][Full Text] [Related]
19. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
[TBL] [Abstract][Full Text] [Related]
20. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W
J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
